Vanda Falls Again As Teva, FDA Win Judgment In ‘Unlawful’ Tasimelteon Approval Case

Originator Argued That Teva’s Hetlioz ANDA Improper Due To Braille Omission On Label

A month after Vanda failed to win a trade secrets case against the US FDA corresponding to generic approvals for its brands Hetlioz and Fanapt, the originator has again fallen, this time to the agency and Teva in the alleged unlawful approval of the Israeli firm’s generic Hetlioz product.

Hand push red Red Cross mark to choose cancellation item , Approve and reject business and document
(Shutterstock)

A US district court in Washington D.C. has ruled in favor of Teva in Vanda Pharmaceuticals’ bid for summary judgment arguing that the US Food and Drug Administration’s approval of Teva’s generic version of the originator’s Hetlioz (tasimelteon) was unlawful, marking another defeat for serial litigator Vanda.

Having joined the suit shortly after it was filed by Vanda against the FDA in 2023, Teva has seen its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

US Federal Circuit Says No To Teva And Viatris On Remanded Invega Sustenna Appeal

 
• By 

Just days after Viatris was frustrated in its attempts to challenge IP protecting Janssen’s Invega Trinza, the US Federal Circuit has rejected the firm’s and Teva’s bid to invalidate a patent shielding the one-month version of the brand, Invega Sustenna.

‘Prescription Drugs Are Not Golf Balls’ – Opinions Clash On Patents During FTC/DOJ Listening Session

 

Pro-innovator voices argued that the number of patents asserted in the pharma industry is not too dissimilar to other fields. But should drugs be compared to golf balls?

Zydus Trastuzumab Suit Dismissed In India For ‘Illusion Of Cause Of Action’

 
• By 

After nearly a decade of procedural delays, a Bombay High Court has finally tossed Zydus Cadila’s pre-emptive complaint against Roche over its Herceptin biosimilar, calling it an “illusion” of a real dispute.

Alchem Fined Over Buscopan API Cartel

 
• By 

After pursuing Alchem International for breaches of EU antitrust rules – relating to a cartel over the SNBB pharmaceutical ingredient used in Buscopan and its generics – the European Commission has now hit the firm with a €489,000 fine.

More from Products